Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from http://www.ncbi.nlm.nih.gov/pubmed/15809411 below:

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children

Comparative Study

Affiliations

• ¹ Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA. huskamp@hcp.med.harvard.edu

• PMID: 15809411
• PMCID: PMC1403292
• DOI: 10.1001/archpsyc.62.4.435

Item in Clipboard

Comparative Study

Haiden A Huskamp et al. Arch Gen Psychiatry. 2005 Apr.

• ¹ Department of Health Care Policy, Harvard Medical School, 180 Longwood Avenue, Boston, MA 02115, USA. huskamp@hcp.med.harvard.edu

• PMID: 15809411
• PMCID: PMC1403292
• DOI: 10.1001/archpsyc.62.4.435

Item in Clipboard

Background: Expenditures for medications used to treat attention-deficit/hyperactivity disorder (ADHD) in children have increased rapidly. Many employers and health plans have adopted 3-tier formularies in an attempt to control costs for these and other drugs.

Objective: To assess the effect of copayment increases associated with 3-tier formulary adoption on use and spending patterns for ADHD medications for children.

Design and setting: Observational study using quasi-experimental design to compare effects on ADHD medication use and spending for children enrolled as dependents in an employer-sponsored plan that made major changes to its pharmacy benefit design and a comparison group of children covered by the same insurer. The plan simultaneously moved from a 1-tier (same copayment required for all drugs) to a 3-tier formulary and implemented an across-the-board copayment increase. The plan later moved 3 drugs from tier 3 to tier 2.

Participants: An intervention group of 20 326 and a comparison group of 15 776 children aged 18 years and younger.

Main outcome measures: Monthly probability of using an ADHD medication; plan, enrollee, and total ADHD medication spending; and medication continuation.

Results: A 3-tier formulary implementation resulted in a 17% decrease in the monthly probability of using medication (P<.001), a 20% decrease in expected total medication expenditures, and a substantial shifting of costs from the plan to families (P<.001). Intervention group children using medications in the pre-period were more likely to change to a medication in a different tier after 3-tier adoption, relative to the comparison group (P = .08). The subsequent tier changes resulted in increased plan spending (P<.001) and decreased patient spending (P = .003) for users but no differences in continuation.

Conclusions: The copayment increases associated with 3-tier formulary implementation by 1 employer resulted in lower total ADHD medication spending, sizeable increases in out-of-pocket expenditures for families of children with ADHD, and a significant decrease in the probability of using these medications.

PubMed Disclaimer

Monthly total spending on attention-deficit/hyperactivity disorder…

Monthly total spending on attention-deficit/hyperactivity disorder medications for children aged 18 years and younger.

Monthly total spending on attention-deficit/hyperactivity disorder medications for children aged 18 years and younger.

• The effect of incentive-based formularies on prescription-drug utilization and spending.

  Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. Huskamp HA, et al. N Engl J Med. 2003 Dec 4;349(23):2224-32. doi: 10.1056/NEJMsa030954. N Engl J Med. 2003. PMID: 14657430

• The effect of a three-tier formulary on antidepressant utilization and expenditures.

  Hodgkin D, Parks Thomas C, Simoni-Wastila L, Ritter GA, Lee S. Hodgkin D, et al. J Ment Health Policy Econ. 2008 Jun;11(2):67-77. J Ment Health Policy Econ. 2008. PMID: 18509214

• Employer drug benefit plans and spending on prescription drugs.

  Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Joyce GF, et al. JAMA. 2002 Oct 9;288(14):1733-9. doi: 10.1001/jama.288.14.1733. JAMA. 2002. PMID: 12365957

• Are incentive-based formularies inversely associated with drug utilization in managed care?

  Gleason PP, Gunderson BW, Gericke KR. Gleason PP, et al. Ann Pharmacother. 2005 Feb;39(2):339-45. doi: 10.1345/aph.1E380. Epub 2005 Jan 11. Ann Pharmacother. 2005. PMID: 15644478 Review.

• Approaches to pharmacy benefit management and the impact of consumer cost sharing.

  Olson BM. Olson BM. Clin Ther. 2003 Jan;25(1):250-72. doi: 10.1016/s0149-2918(03)90035-x. Clin Ther. 2003. PMID: 12637125 Review.

• Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature - 2001-2007.

  Lu CY, Ross-Degnan D, Soumerai SB, Pearson SA. Lu CY, et al. BMC Health Serv Res. 2008 Apr 7;8:75. doi: 10.1186/1472-6963-8-75. BMC Health Serv Res. 2008. PMID: 18394200 Free PMC article.

• Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.

  Shen C, Zhao B, Liu L, Shih YT. Shen C, et al. Cancer. 2018 Jan 15;124(2):364-373. doi: 10.1002/cncr.31050. Epub 2017 Oct 4. Cancer. 2018. PMID: 28976559 Free PMC article.

• A comparison between the effects of drug costs and share of family income on drug costs in determining drug price.

  Dong X, Tsang CCS, Kotian A, Zeng J, Tran M, Wang J. Dong X, et al. Medicine (Baltimore). 2021 Aug 6;100(31):e26877. doi: 10.1097/MD.0000000000026877. Medicine (Baltimore). 2021. PMID: 34397865 Free PMC article.

• Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.

  Fullerton CA, Epstein AM, Frank RG, Normand SL, Fu CX, McGuire TG. Fullerton CA, et al. Psychiatr Serv. 2012 Feb 1;63(2):115-21. doi: 10.1176/appi.ps.201100095. Psychiatr Serv. 2012. PMID: 22302327 Free PMC article.

• Comparison of tiered formularies and reference pricing policies: a systematic review.

  Morgan S, Hanley G, Greyson D. Morgan S, et al. Open Med. 2009;3(3):e131-9. Epub 2009 Aug 4. Open Med. 2009. PMID: 21603047 Free PMC article.

1. 1. American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033–1044. - PubMed
2. 1. Biederman J. Practical considerations in stimulant drug selection for the attention-deficit/hyperactivity disorder patient–efficacy, potency and titration. Today’s Therapeutic Trends. 2002;20:311–328.
3. 1. Medco Health Solutions Inc. 2004 Drug Trend Report: Navigating the New Health Economy. Franklin Lakes, NJ: Medco Health Solutions Inc; 2004:5–27.
4. 1. Frank R. Prescription drug prices: why do some pay more than others do? Health Aff (Millwood) 2001;20:115–128. - PubMed
5. 1. Kaiser Family Foundation and the Health Research and Educational Trust. Employer Health Benefits 2004 Annual Report. Available at: http://www.kff.org/insurance/7148/index.cfm Accessed February 1, 2005.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3